These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24850342)

  • 1. Baseline low modified health assessment questionnaire (MHAQ) predicts the state of remission estimated by clinical disease activity index and MHAQ at 1 year in tocilizumab-treated rheumatoid arthritis patients.
    Kawashiri S; Ueki Y; Migita K; Nakamura H; Aoyagi K; Kawakami A
    Clin Exp Rheumatol; 2014; 32(3):445. PubMed ID: 24850342
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
    Kawashiri SY; Nishino A; Suzuki T; Nakashima Y; Horai Y; Ueki Y; Aramaki T; Fujikawa K; Nakashima M; Okada A; Migita K; Mizokami A; Matsuoka N; Mine M; Sakito S; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Aoyagi K; Eguchi K; Kawakami A
    Clin Exp Rheumatol; 2016; 34(5):808-812. PubMed ID: 27384149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subclinical inflammation with tocilizumab treatment of rheumatoid arthritis: MRI evaluation for 2 years.
    Suzuki T; Hirota T; Ogishima H; Umeda N; Kondo Y; Yokosawa M; Miki H; Tsuboi H; Matsumoto I; Sumida T
    Int J Rheum Dis; 2015 Jan; 18(1):108-10. PubMed ID: 25294091
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study.
    Terenzi R; Santoboni G; Bartoloni E; Alunno A; Luccioli F; Gerli R
    Clin Exp Rheumatol; 2015; 33(3):445. PubMed ID: 25937244
    [No Abstract]   [Full Text] [Related]  

  • 6. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy.
    Nishina N; Kikuchi J; Hashizume M; Yoshimoto K; Kameda H; Takeuchi T
    Ann Rheum Dis; 2014 May; 73(5):945-7. PubMed ID: 24336338
    [No Abstract]   [Full Text] [Related]  

  • 7. Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: prognostic factors after two years of follow-up.
    Graell E; Vazquez I; Larrosa M; Rodríguez-Cros JR; Hernández MV; Gratacós J; Gómez A; Cañete JD; Gómez-Puerta JA; Sanmartí R
    Clin Exp Rheumatol; 2009; 27(2):284-91. PubMed ID: 19473570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
    Kojima T; Yabe Y; Kaneko A; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Asai S; Hirabara S; Asai N; Hirano Y; Hayashi M; Miyake H; Kojima M; Ishiguro N
    Rheumatology (Oxford); 2015 Jan; 54(1):113-20. PubMed ID: 25102861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis.
    Nagasawa H; Kameda H; Sekiguchi N; Amano K; Takeuchi T
    Mod Rheumatol; 2010 Aug; 20(4):337-42. PubMed ID: 20225006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced dose of tocilizumab for the maintenance of remission in patients with rheumatoid arthritis: a clinical experience.
    Epis O; Casu C; Belloli L; Schito E; Filippini D; Muscarà M; Bruschi E
    Rheumatol Int; 2015 Sep; 35(9):1569-70. PubMed ID: 25773656
    [No Abstract]   [Full Text] [Related]  

  • 11. Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.
    Gossec L; Steinberg G; Rouanet S; Combe B
    Clin Exp Rheumatol; 2015; 33(5):664-70. PubMed ID: 26344671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab.
    Hoshi D; Nakajima A; Shidara K; Seto Y; Tanaka E; Taniguchi A; Momohara S; Yamanaka H
    Mod Rheumatol; 2013 Nov; 23(6):1205-10. PubMed ID: 23456321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice.
    Narváez J; Magallares B; Díaz Torné C; Hernández MV; Reina D; Corominas H; Sanmartí R; LLobet JM; Rodriguez de la Serna A; Nolla JM
    Semin Arthritis Rheum; 2016 Feb; 45(4):386-90. PubMed ID: 26254548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumab.
    Fusama M; Nakahara H; Hamano Y; Nishide M; Kawamoto K; Hosokawa T; Nozato S; Higa S; Igarashi T; Takeuchi E; Kuroiwa T; Shimaoka Y; Yukioka M; Miura Y; Higashi K; Kuritani T; Maeda K
    Mod Rheumatol; 2013 Mar; 23(2):276-83. PubMed ID: 22669600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice.
    Kojima T; Kaneko A; Hirano Y; Ishikawa H; Miyake H; Takagi H; Yabe Y; Kato T; Terabe K; Fukaya N; Tsuchiya H; Shioura T; Funahashi K; Hayashi M; Kato D; Matsubara H; Ishiguro N
    Mod Rheumatol; 2012 Jun; 22(3):370-5. PubMed ID: 21931942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis.
    Ammitzbøll CG; Thiel S; Jensenius JC; Ellingsen T; Hørslev-Petersen K; Hetland ML; Junker P; Krogh NS; Østergaard M; Stengaard-Pedersen K
    Arthritis Rheum; 2013 Dec; 65(12):3045-50. PubMed ID: 24022747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study.
    Yabe Y; Kojima T; Kaneko A; Asai N; Kobayakawa T; Ishiguro N
    Mod Rheumatol; 2013 Mar; 23(2):245-53. PubMed ID: 22526833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
    J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis.
    Aguilar-Lozano L; Castillo-Ortiz JD; Vargas-Serafin C; Morales-Torres J; Sanchez-Ortiz A; Sandoval-Castro C; Padilla-Ibarra J; Hernandez-Cuevas C; Ramos-Remus C
    J Rheumatol; 2013 Jul; 40(7):1069-73. PubMed ID: 23729804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.
    Kremer JM; Blanco R; Halland AM; Brzosko M; Burgos-Vargas R; Mela CM; Rowell L; Fleischmann RM
    Clin Exp Rheumatol; 2016; 34(4):625-33. PubMed ID: 27087059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.